Overnight hypoxic exposure and glucagon-like peptide-1 and leptin levels in humans

Snyder, Eric M.; Carr, Richard D.; Deacon, Carolyn F.; Johnson, Bruce D.
October 2008
Applied Physiology, Nutrition & Metabolism;Oct2008, Vol. 33 Issue 5, p929
Academic Journal
Altitude exposure has been associated with loss of appetite and weight loss in healthy humans; however, the endocrine factors that contribute to these changes remain unclear. Leptin and glucagon-like peptide-1 (GLP-1) are peptide hormones that contribute to the regulation of appetite. Leptin increases with hypoxia; however, the influence of hypoxia on GLP-1 has not been studied in animals or humans to date. We sought to determine the influence of normobaric hypoxia on plasma leptin and GLP-1 levels in 25 healthy humans. Subjects ingested a control meal during normoxia and after 17 h of exposure to normobaric hypoxia (fraction of inspired oxygen of 12.5%, simulating approximately 4100 m). Plasma leptin was assessed before the meal, and GLP-1 was assessed premeal, at 20 min postmeal, and at 40 min postmeal. We found that hypoxia caused a significant elevation in plasma leptin levels (normoxia, 4.9 ± 0.8 pg·mL-1; hypoxia, 7.7 ± 1.5 pg·mL-1; p < 0.05; range, -16% to 190%), no change in the average GLP-1 response to hypoxia, and only a small trend toward an increase in GLP-1 levels 40 min postmeal (fasting, 15.7 ± 0.9 vs 15.9 ± 0.7 pmol·L-1; 20 min postmeal, 21.7 ± 0.9 vs 21.8 ± 1.2 pmol·L-1; 40 min postmeal, 19.5 ± 1.2 vs. 21.0 ± 1.2 pmol·L-1 for normoxia and hypoxia, respectively; p > 0.05 normoxia vs hypoxia). There was a correlation between SaO2 and leptin after the 17 h exposure (r = 0.45; p < 0.05), but no relation between SaO2 and GLP-1. These data confirm that leptin increases with hypoxic exposure in humans. Further study is needed to determine the influence of hypoxia and altitude on GLP-1 levels.


Related Articles

  • Can PYY cure obesity? Fields, Helen // U.S. News & World Report;9/15/2003, Vol. 135 Issue 8, p49 

    States that PYY, which stands for Peptide YY[sub3-36], has potential for developing weight-loss drugs. How the hormone is made and travels to the brain indicate when to stop eating; Mention of research in Great Britain that suggests people eat less with PYY; Background on research into appetite...

  • Leptin and the obesity hypoventilation syndrome: a leap of faith? Fitzpatrick, M. // Thorax;Jan2002, Vol. 57 Issue 1, p1 

    The discovery of the anti-obesity hormone leptin, has fuelled a recent surge of interest in the mechanisms regulating mammalian fat stores. Leptin, a 16 kD protein of 167 amino acids with a similar crystal structure to cytokines, is produced primarily by white adipose tissue. The hormone elicits...

  • Cisplatin/gimeracil/oteracil/tegafur.  // Reactions Weekly;3/10/2012, Issue 1392, p17 

    The article describes the case of a woman in her 60s who developed loss of appetite and vomiting while receiving gimeracil/oteracil/tegafur and cisplatin for gastric cancer.

  • Sirolimus.  // Reactions Weekly;3/10/2012, Issue 1392, p41 

    The article describes the case of a 65-year-old female liver transplant recipient who developed new-onset ascites, nausea, anorexia and abdominal discomfort 4 weeks after her therapy was switched from immunosuppression with tacrolimus to sirolimus.

  • Leptin and Nitric Oxide in Blood Pressure Regulation in Humans. Tsuda, Kazushi // American Journal of Hypertension;Nov2014, Vol. 27 Issue 11, p1428 

    A letter to the editor is presented in response to the article "Leptin in association with common variants of MC3R mediates hypertension," by M. Melhelm and colleagues in the 2014 issue is presented.

  • Pramlintide as a Weight-Loss Adjunct.  // Clinical Oncology Alert;Nov2008 Primary Care Supplement, p22 

    The article discusses research being done on pramlintide as a weight-loss adjunct. It references a study by Smith et al. published in a 2008 issue of "Diabetes Care." The researchers performed a double-blind, placebo-controlled trial of various doses of subcutaneous pramlintide in obese,...

  • Acamprosate.  // Reactions Weekly;3/10/2012, Issue 1392, p5 

    The article describes the case of three patients who developed either anorexia or nausea following administration of oral acamprosate, for social impairment associated with autism.

  • Leptin and insulin responses to a four-day energy-deficient diet in men with different weight history. Mars, M; de Graaf, C; van Rossum, C T M; de Groot, C P G M; Seidell, J C; Kok, F J // International Journal of Obesity & Related Metabolic Disorders;May2003, Vol. 27 Issue 5, p574 

    OBJECTIVE:: To assess the leptin responses to a 4-day energy-restricted diet in men with different weight history; high retrospective weight gain was expected to be associated with a small decline in leptin. DESIGN:: Changes in fasting leptin and insulin were measured during a 4-day controlled...

  • Leptin in the Pathophysiology of Human Obesity and the Clinical Potential of Leptin-Based Therapy. Thorburn, A.W.; Ainslie, D.A.; Fam, B.; Proietto, J. // BioDrugs;2000, Vol. 13 Issue 6, p391 

    Leptin is a circulating hormone that is secreted in proportion to fat mass. It can reduce bodyweight by activating signalling molecules in the brain. Leptin appears to affect bodyweight primarily by decreasing food intake; there is no direct evidence that it significantly influences energy...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics